Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study

BACKGROUND: On Dec 20, 2020, Israel initiated a nationwide COVID-19 vaccination campaign for people aged 16 years and older and exclusively used the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine (tozinameran). We provide estimates of the number of SARS-CoV-2 infections and COVID-19-related admissio...

Descripción completa

Detalles Bibliográficos
Autores principales: Haas, Eric J, McLaughlin, John M, Khan, Farid, Angulo, Frederick J, Anis, Emilia, Lipsitch, Marc, Singer, Shepherd R, Mircus, Gabriel, Brooks, Nati, Smaja, Meir, Pan, Kaijie, Southern, Jo, Swerdlow, David L, Jodar, Luis, Levy, Yeheskel, Alroy-Preis, Sharon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457761/
https://www.ncbi.nlm.nih.gov/pubmed/34562375
http://dx.doi.org/10.1016/S1473-3099(21)00566-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457761/
https://www.ncbi.nlm.nih.gov/pubmed/34562375
http://dx.doi.org/10.1016/S1473-3099(21)00566-1

Ejemplares similares